Clinical Trial

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, placebo-controlled, single dose, dose-escalation phase 1 study to evaluate the safety, pharmacokinetics and antiviral activity of a highly potent neutralizing anti-HBV monoclonal antibody (mAb), HepB mAb19, which targets the S-protein in individuals with chronic hepatitis B (CHB) on nucleos(t)ide analog therapy (NRTI).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-05-03; most recent amendment 2026-01-29.
Status change: Not Yet Recruiting → Recruiting 2023-08-07
Trial Details
NCT Number NCT05856890
Lead Sponsor Rockefeller University
Collaborators: NYU Langone Health
Conditions Hepatitis b Virus, Hepatitis B
Enrollment 37 participants
Start Date 2023-08-07
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-02